Puma Biotechnology (PBYI) Receivables (2016 - 2026)

Puma Biotechnology (PBYI) has 11 years of Receivables data on file, last reported at $26.3 million in Q1 2026.

• Quarterly Receivables rose 2.26% year-over-year to $26.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.3 million (up 2.26% YoY) and the FY2025 annual result came in at $53.7 million, up 67.61% from the prior year.
• Receivables slipped to $26.3 million in Q1 2026, from $53.7 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $55.4 million in Q3 2024 to a low of $25.6 million in Q1 2024.
• A 5-year average of $33.9 million and a median of $31.2 million in 2023 frame the typical range for Receivables.
• Annual changes were most pronounced in 2024 — Receivables soared 91.22% — and 2025, when it sank 39.42%.
• Tracing PBYI's Receivables over 5 years: stood at $40.4 million in 2022, then grew by 18.56% to $47.8 million in 2023, then sank by 33.08% to $32.0 million in 2024, then surged by 67.61% to $53.7 million in 2025, then sank by 50.93% to $26.3 million in 2026.
• The last three Receivables figures came in at $26.3 million (Q1 2026), $53.7 million (Q4 2025), and $33.6 million (Q3 2025), per Business Quant data.